One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

Phase 4 Terminated 172 enrolled Viatris Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.

Timeline

Start: 2008-12
Primary completion: 2012-05
Completion: 2012-05

Publications

Chue P, Mandel FS, Therrien F. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. Curr Med Res Opin. 2014 Jun;30(6):997-1005. doi: 10.1185/03007995.2014.898139. Epub 2014 Mar 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ziprasidone	Small molecule	20 mg	Oral
Subject	Ziprasidone	Small molecule	80 mg	Oral

One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

Summary

Timeline

Publications

Drugs

Indications